AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$ESLA

Estrella Immunopharma, Inc.

Price · $ESLAvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $ESLA in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $ESLA in the last 30 days.

Top stories · $ESLAMore →
MAY 1·Stock TitanLow

Eureka-led Estrella (NASDAQ: ESLA) details 59.3% control and board pay

Estrella Immunopharma (NASDAQ: ESLA) filed an amended annual report (10-K/A) for the fiscal year ended December 31, 2025, providing detailed disclosures on board composition, executive compensation, beneficial ownership, and auditor matters. The filing revealed that CEO Dr. Cheng Liu and CFO Peter Xu each earned $250,962 in salary for 2025, and that Eureka Therapeutics, Inc. beneficially owns approximately 59.3% of Estrella's common stock, classifying it as a "controlled company" under Nasdaq rules.

JAN 14·Investing.com

Estrella Immunopharma receives Nasdaq notice for delayed annual meeting

Estrella Immunopharma, Inc. received a Nasdaq notice for non-compliance with the rule requiring annual shareholder meetings, having 45 days to submit a compliance plan. The company plans to hold its meeting in April 2026 but acknowledges no assurance of Nasdaq's approval. This notice does not immediately affect its stock listing, and follows recent news of a successful $8 million direct offering and clearance for its EB103 cancer therapy to Phase II clinical trials.

News on $ESLA

All news →